Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from dedicated technical support and regulatory assistance throughout the procurement process.

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain cancers.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by blocking BCR‑ABL signaling. - Gastrointestinal stromal tumor (GIST): limits tumor growth by inhibiting c‑KIT and PDGFR pathways.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools. - Edema: swelling, often in the extremities. - Fatigue: generalized tiredness. - Muscle cramps: occasional tightness in muscles. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: decreased left ventricular ejection fraction. - Severe neutropenia: markedly low white blood cell count. - Thrombocytopenia: reduced platelet count leading to bleeding risk. - Anaphylaxis: rare allergic reaction requiring immediate medical attention.

Before initiating Imatinib therapy, several safety considerations should be reviewed. - Baseline liver function: assess hepatic enzymes to detect pre‑existing impairment. - Cardiac assessment: evaluate ejection fraction in patients with known heart disease. - Hematologic monitoring: perform regular blood counts to detect neutropenia or thrombocytopenia. - Drug interactions: review concomitant medications that may affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Imatinib interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce Imatinib plasma levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase exposure and risk of toxicity. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly lower bioavailability; separate dosing by at least 2 hours. - Warfarin: enhanced anticoagulant effect; monitor INR closely. - Diuretics: potential for increased serum potassium changes; observe electrolytes.